GLORIA

GEOMAR Library Ocean Research Information Access

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Evaluation of plasma 5-fluorouracil nucleoside levels in patients with metastatic breast cancer: relationships with toxicities (1995)
    Springer
    Cancer chemotherapy and pharmacology 37 (1995), S. 110-116 
    Details
    ISSN: 1432-0843
    Keywords: Key words 5-Fluorouracil ; Anabolites ; 5-Fluorouridine ; 5-Fluoro-2′-deoxyuridine ; Breast cancer ; Toxic side effects
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract  This paper describes the relationship between 5-fluorouracil (FUra)–derived toxicities and plasma levels of the FUra anabolites 5-fluorouridine (FUrd) and 5-fluoro-2′-deoxyuridine (FdUrd) monitored in patients receiving continuous infusions of FUra (1000 mg/m2 per 24 h) over 5 days preceded by the administration of cisplatin (100 mg/m2) . A total of 63 courses of this treatment were given as second-line chemotherapy to 17 patients with metastatic breast cancer. The active FUra anabolites FUrd and FdUrd were monitored twice daily in the plasma by high-performance liquid chromatography. Data were analyzed using multiple analysis of variance (ANOVA). Only a low proportion of patients exhibited measurable plasmatic levels of FUrd (43%) and FdUrd (70%). The areas under the plasma concentration-time curves (AUC) determined over 120 h for FUrd (AUCFUrd) and for FdUrd (AUCFdUrd) were found to be statistically significantly different for chemotherapy cycles with and those without myelosuppression. Chemotherapy cycles without neutropenia were associated with low AUCFUrd values (mean ± SEM, 2.9±0.7 μg ml-1 h) and high AUCFdUrd values (14.1±2.7 μg ml-1 h) , respectively, whereas courses with myelosuppression (WHO grades 2–4) showed inverse profiles with high AUCFUrd values (16.3±2.3 μg ml-1 h) and low AUCFdUrd values (3.1±1.0 μg ml-1 h), respectively. A statistically significant difference in AUCFdUrd values was also observed between cycles with and those without mucositis (P=0.0027), with AUCFdUrd values being 22.6±5.6 and 7.8±1.9 μg ml-1 h, respectively. Whereas hematotoxicity could be correlated with both AUCFUrd and AUCFdUrd values, mucositis was associated with high AUCFdUrd levels. Moreover, a negative correlation was found between the AUCs determined for FUrd and FdUrd (P=0.002) , indicating that activation of FUra via FUrd or via FdUrd may involve competitive processes. Therefore, to follow the development of the major FUra-derived toxicities, measurement of FUrd and FdUrd plasma levels appeared very attractive.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s002800050375
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Evaluation of plasma 5-fluorouracil nucleoside levels in patients with metastatic breast cancer: relationships with toxicities (1995)
    Springer
    Cancer chemotherapy and pharmacology 37 (1995), S. 110-116 
    Details
    ISSN: 1432-0843
    Keywords: 5-fluorouracil ; Anabolites ; 5-fluorouridine ; 5-fluoro-2′-deoxyuridine ; Breast cancer ; Toxic side effects
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract This paper describes the relationship between 5-fluorouracil (FUra)-derived toxicities and plasma levels of the FUra anabolites 5-fluorouridine (FUrd) and 5-fluoro-2′-deoxyuridine (FdUrd) monitored in patients receiving continuous infusions of FUra (1000 mg/m2 per 24 h) over 5 days preceded by the administration of cisplatin (100 mg/m2). A total of 63 courses of this treatment were given as second-line chemotherapy to 17 patients with metastatic breast cancer. The active FUra anabolites FUrd and FdUrd were monitored twice daily in the plasma by highperformance liquid chromatography. Data were analyzed using multiple analysis of variance (ANOVA). Only a low proportion of patients exhibited measurable plasmatic levels of FUrd (43%) and FdUrd (70%). The areas under the plasma concentration-time curves (AUC) determined over 120 h for FUrd (AUCFUrd) and for FdUrd (AUCFdUrd) were found to be statistically significantly different for chemotherapy cycles with and those without myelosuppression. Chemotherapy cycles without neutropenia were associated with low AUCFUrd values (mean±SEM, 2.9±0.7 μg ml−1 h) and high AUCFdUrd values (14.1±2.7 μg ml−1 h), respectively, whereas courses with myelosuppression (WHO grades 2–4) showed inverse profiles with high AUCFUrd values (16.3±2.3 μg ml−1 h) and low AUCFdUrd values (3.1±1.0 μg ml−1 h), respectively. A statistically significant difference in AUCFdUrd values was also observed between cycles with and those without mucositis (P=0.0027), with AUCFdUrd values being 22.6±5.6 and 7.8±1.9 μg ml−1 h, respectively. Whereas hematotoxicity could be correlated with both AUCFUrd and AUCFdUrd values, mucositis was associated with high AUCFdUrd levels. Moreover, a negative correlation was found between the AUCs determined for FUrd and FdUrd (P=0.002), indicating that activation of FUra via FUrd or via FdUrd may involve competitive processes. Therefore, to follow the development of the major FUra-derived toxicities, measurement of FUrd and FdUrd plasma levels appeared very attractive.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00685637
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Long-term response to human growth hormone in 36 children with idiopathic growth hormone deficiency (1979)
    Springer
    European journal of pediatrics 132 (1979), S. 221-238 
    Details
    ISSN: 1432-1076
    Keywords: Idiopathic growth hormone deficiency ; Diagnosis ; Aetiology ; Treatment ; Prognosis
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract The results of long term treatment with human growth hormone (Crescormon®, 12.4 IU/m2/week) in 36 patients with idiopathic growth hormone deficiency are given. Birth trauma—in particular assisted breech delivery (30%)—is the major aetiological cause. Twelve patients had isolated growth hormone deficiency (IGHD), 24 had multiple pituitary hormone deficiencies (MPHD) of which 19 were treated with additional thyroid hormones. The results were judged by the criteria of height velocity, total height gain and change of height prediction (TW2, age based). It is concluded that the growth hormone dose chosen in many cases is insufficient to maintain high growth rates after the first year of treatment, when “catch-up” no longer takes place. The tendency of patients supplemented with thyroid hormone to grow better—without additional bone-age advancement—calls for careful search for hypothyroidism and suggests the use of thyroxin in cases of doubt.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00496846
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Multiple metachronous skin squamous cell carcinomas and epidermodysplasia verruciformis in the head region: a human papilloma virus-associated disease (1994)
    Springer
    European archives of oto-rhino-laryngology and head & neck 251 (1994), S. 342-346 
    Details
    ISSN: 1434-4726
    Keywords: epidermodysplasia verruciformis ; Human papilloma virus ; Head and neck ; Diagnosis ; Treatment In situ hybridization
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Data from a young adult man with epidermodysplasia verruciformis (EV) and multiple metachronous spinaliomas in the head and neck region are presented. Diagnosis of this rare, human papilloma virus (HPV)-associated disease was based on: (1) Typical skin lesions, including viral warts, verruca plana-type lesions and pityriasis versicilor; (2) typical histological features, including ‘foamy giant keratinocytes”; (3) evidence of HPV 5, 8 and 20 in pityriasis versicilor-like lesions; (4) a cellular immunodeficiency due to a relative T-helper-cell deficit. No specific treatment of EV is known, so that therapy concentrates on early removal of spinaliomas and treatment of intercurrent infections. Since EV patients have numerous benign skin lesions and frequently develop metastatic and non-metastatic carcinomas, molecular changes of HPV during carcinogenesis can be studied.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00171541
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...